Skip to main content

ASCIA Submissions 2025

ASCIA advocates on behalf of ASCIA members and their patients/carers to government and other organisations by lodging submissions which are listed below.

28 May 2025: ASCIA lodged 4 letters of support for review at the July 2025 meeting of the Pharmaceutical Benefits Advisory Committee (PBAC):

  • Pharmaceutical Benefits Scheme (PBS) listing of Joenja® (leniolisib) for treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)
  • Pharmaceutical Benefits Scheme (PBS) listing of aZematop® (tacrolimus) for treatment of moderate to severe atopic dermatitis
  • National Immunisation Program (NIP) listing of Arexvy® Respiratory Syncytial Virus (RSV) Vaccine for the prevention of lower respiratory tract disease caused by RSV in older adults
  • Pharmaceutical Benefits Scheme (PBS) listing of Nemluvio® (Nemolizumab) for the treatment of severe atopic dermatitis (eczema) - A joint communication by ASCIA, Allergy & Anaphylaxis Australia and the National Allergy Council

19 May 2025: A joint communication to the Therapeutic Goods Administration (TGA) was submitted by ASCIA, Allergy & Anaphylaxis Australia and the National Allergy Council in support of neffy® adrenaline devices.

19 May 2025: A joint communication to the Therapeutic Goods Administration (TGA) was submitted by ASCIA, Allergy & Anaphylaxis Australia and the National Allergy Council in support of neffy® adrenaline devices to be available as Schedule 3 medications in Australia.

9 April 2025: A joint communication was submitted by ASCIA, Allergy & Anaphylaxis Australia and the National Allergy Council to Virgin Australia Ltd, regarding the proposed amendment to allow airline passengers to travel with companion dogs and cats in the aircraft cabin. Virgin Australia has provided a detailed response.

27 March 2025: ASCIA submitted a new application to the Medical Services Advisory Committee (MSAC) for a Medical Benefits Schedule (MBS) item number for supervised oral food challenges (OFC), as part of the National Allergy Council projects that are assigned to ASCIA. 

10 March 2025: A joint communication was submitted by ASCIA, Allergy & Anaphylaxis Australia and the National Allergy Council to the Hon Mark Butler MP, Minister for Health and Aged Care, Parliament of Australia, regarding Telehealth Post-Implementation Review Final Report - Recommendation 10a.

10 March 2025: ASCIA lodged a letter of support for the following Medical Services Advisory Committee (MSAC) application by the Royal College of Pathologists of Australasia (RCPA) for genomic testing for the diagnosis of inborn errors of immunity (IEI) including primary immunodeficiency diseases (PID). 

10 March 2025: ASCIA lodged a letter of support for the following application, for review at the May 2025 Pharmaceutical Benefits Advisory Committee (PBAC) meeting:

24 February 2025: A joint communication was submitted to the Pharmaceutical Benefits Advisory Committee (PBAC) regarding the importance of amino acid formula being listed on the PBS for patients with cow’s milk allergy, from ASCIA, Allergy & Anaphylaxis Australia and the National Allergy Council.

20 February 2025: ASCIA responded to a survey conducted by HealthConsult on behalf of the National Blood Authority (NBA) regarding the development of the Ig Prioritisation Framework (the Framework), which will guide decision-making and allocation of immunoglobulin (Ig) in the event of a supply shortage.

17 February 2025: A joint communication was submitted to the ACT Government regarding the need for a public paediatric allergy clinic in the ACT, from ASCIA, Allergy & Anaphylaxis Australia (A&AA) and the National Allergy Council.

23 January 2025: ASCIA lodged five letters of support on  for the following applications, for review at the March 2025 Pharmaceutical Benefits Advisory Committee (PBAC) meeting:

January 2025: ASCIA provided two letters of support for allergy/immunology departments to the World Allergy Organisation (WAO) Center pf Excellence program. 

2025